摘要
目的探讨微创靶向综合疗法治疗难治性肺结核的近远期疗效和原理。方法 348例难治性肺结核病人均为该院2008~2012年住院病人,全部采用该院独立研究的微创靶向综合疗法进行诊治,其临床资料经系统调查问卷分析整理和6个月以上的追踪观察。结果 348例难治性肺结核患者经治疗3个月结束时,痰菌转阴率达95.7%,病灶吸收率为93.6%,空洞闭合率72.6%,总有效率(空洞闭合+缩小)为96.9%。348例难治性肺结核病人完成疗程后半年的随访资料显示,有5例复发,复发率为1.5%。平均治愈率为86.3%,平均治愈时间为68 d,平均治愈费用38 796元。明显优于同类文献研究数据。结论微创靶向综合疗法是目前国内外快速治愈难治性肺结核的有效方法,与传统化学疗法比较,不仅疗效显著,适应证广泛,复发率极低,而且治疗时间短、副作用小、费用低廉,值得认真推广。
[ Objective ] To explore the short- and long-term effect and principle of MIT-TB for the treatment of refractory pulmonary tuberculosis. [Methods] During the period between 2008 and 2012, 348 patients with refrac- tory pulmonary tuberculosis were all treated by MIT-TB which was invented independently by Shenzhen Shanxia Hospital. The clinical data of these cases were analyzed through questionnaires and a six-month follow-up study. [ Results ] After 3 months of MIT-TB therapy, the sputum negative conversion rate was 95.7%, the loci absorption rate was 93.6%, the cavity closure rate was 72.6%, and the total effect rate （the cavity closure and reduction） was 96.9%. Recurrence rate in 6 months after the treatment was 1.5%（5 cases）. The average cure rate was 86.3%, the average cure time was 68 days, and the average cost of treatment was 38 796 RMB. Clearly, the results were much better than those from similar documents. [ Conclusion ] MIT-TB is the most effective treatment of refractory pul- monary tuberculosis around the world. Compared with traditional therapies, MIT-TB not only has better therapeutic effect, wider indications, lower recurrence rate and fewer side effects, but also has shorter treatment time and less treatment cost. Therefore, it absolutely deserves vigorous promotion.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2014年第1期97-102,共6页
China Journal of Modern Medicine
